Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

A Plasma Concentration of α-Ketoglutarate Influences the Kinetic Interaction of Ligands with Organic Anion Transporter 1

Leslie Ingraham, Mansong Li, J. Larry Renfro, Sonda Parker, Arpine Vapurcuyan, Imad Hanna and Ryan M. Pelis
Molecular Pharmacology July 2014, 86 (1) 86-95; DOI: https://doi.org/10.1124/mol.114.091777
Leslie Ingraham
Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada (L.I., M.L., R.M.P.); Department of Physiology and Neurobiology, University of Connecticut, Storrs, Connecticut (J.L.R., S.P.); and Department of Drug Metabolism and Pharmacokinetics, Novartis Institutes for Biomedical Research, East Hanover, New Jersey (A.V., I.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mansong Li
Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada (L.I., M.L., R.M.P.); Department of Physiology and Neurobiology, University of Connecticut, Storrs, Connecticut (J.L.R., S.P.); and Department of Drug Metabolism and Pharmacokinetics, Novartis Institutes for Biomedical Research, East Hanover, New Jersey (A.V., I.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Larry Renfro
Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada (L.I., M.L., R.M.P.); Department of Physiology and Neurobiology, University of Connecticut, Storrs, Connecticut (J.L.R., S.P.); and Department of Drug Metabolism and Pharmacokinetics, Novartis Institutes for Biomedical Research, East Hanover, New Jersey (A.V., I.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonda Parker
Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada (L.I., M.L., R.M.P.); Department of Physiology and Neurobiology, University of Connecticut, Storrs, Connecticut (J.L.R., S.P.); and Department of Drug Metabolism and Pharmacokinetics, Novartis Institutes for Biomedical Research, East Hanover, New Jersey (A.V., I.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arpine Vapurcuyan
Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada (L.I., M.L., R.M.P.); Department of Physiology and Neurobiology, University of Connecticut, Storrs, Connecticut (J.L.R., S.P.); and Department of Drug Metabolism and Pharmacokinetics, Novartis Institutes for Biomedical Research, East Hanover, New Jersey (A.V., I.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Imad Hanna
Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada (L.I., M.L., R.M.P.); Department of Physiology and Neurobiology, University of Connecticut, Storrs, Connecticut (J.L.R., S.P.); and Department of Drug Metabolism and Pharmacokinetics, Novartis Institutes for Biomedical Research, East Hanover, New Jersey (A.V., I.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan M. Pelis
Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada (L.I., M.L., R.M.P.); Department of Physiology and Neurobiology, University of Connecticut, Storrs, Connecticut (J.L.R., S.P.); and Department of Drug Metabolism and Pharmacokinetics, Novartis Institutes for Biomedical Research, East Hanover, New Jersey (A.V., I.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

The purpose of the present study was to determine whether a physiologic plasma concentration of α-ketoglutarate (αKG) influences the kinetic interaction of ligands with organic anion transporter 1 (OAT1). The effect of extracellular αKG on the kinetics of para-aminohippurate (PAH) and cidofovir transport was examined along with its effect on the potency of 10 drugs in five different classes (uricosuric, nonsteroidal anti-inflammatories, loop diuretics, angiotensin II receptor antagonists, and β-lactam antibiotics) to inhibit OAT1 expressed in Chinese hamster ovary cells. Extracellular αKG competitively inhibited PAH and cidofovir transport with Ki values (∼5 μM) approximating its unbound plasma concentration (determined by equilibrium dialysis). When PAH was the substrate, extracellular αKG (5 μM) significantly increased IC50 values for some inhibitors (up to 4-fold), such as probenecid, but not for others (an inhibitor-dependent effect). For some inhibitors, a significant increase in IC50 value was observed when cidofovir was the substrate, but not PAH (a substrate-dependent effect). A significant increase in IC50 value was also observed for inhibition of PAH transport by probenecid in renal basolateral membrane vesicles (5.2-fold). The substrate- and inhibitor-dependent effect of extracellular αKG on ligand interactions with OAT1 highlights the complexity of the OAT1 ligand-binding surface. The effect of extracellular αKG on the potency of OAT1 inhibition should be considered when assessing drug-drug interaction potential at the transporter.

Footnotes

    • Received January 10, 2014.
    • Accepted April 25, 2014.
  • This work was supported by the Canadian Institutes of Health Research [Grant 286509]; the Nova Scotia Health Research Foundation [Grant MED-EST-2013-9003]; and the US National Science Foundation [Grant 0843253].

  • dx.doi.org/10.1124/mol.114.091777.

  • ↵Embedded ImageThis article has supplemental material available at molpharm.aspetjournals.org.

  • Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 86 (1)
Molecular Pharmacology
Vol. 86, Issue 1
1 Jul 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Plasma Concentration of α-Ketoglutarate Influences the Kinetic Interaction of Ligands with Organic Anion Transporter 1
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

α-Ketoglutarate Affects Ligand Interactions with OAT1

Leslie Ingraham, Mansong Li, J. Larry Renfro, Sonda Parker, Arpine Vapurcuyan, Imad Hanna and Ryan M. Pelis
Molecular Pharmacology July 1, 2014, 86 (1) 86-95; DOI: https://doi.org/10.1124/mol.114.091777

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

α-Ketoglutarate Affects Ligand Interactions with OAT1

Leslie Ingraham, Mansong Li, J. Larry Renfro, Sonda Parker, Arpine Vapurcuyan, Imad Hanna and Ryan M. Pelis
Molecular Pharmacology July 1, 2014, 86 (1) 86-95; DOI: https://doi.org/10.1124/mol.114.091777
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Polypharmacology of CBL0137 in the African Trypanosome
  • Peptide-mediated differential signaling at GPR83
  • Therapeutic Effects of FGF23 Antagonists in Hyp Mice
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics